Roth Capital Comments on Moleculin Biotech, Inc.’s Q2 2024 Earnings (NASDAQ:MBRX)
Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) – Research analysts at Roth Capital boosted their Q2 2024 EPS estimates for Moleculin Biotech in a note issued to investors on Monday, May 13th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($2.10) for the quarter, up from their […]
More Stories
Emily in Paris Season 6: Netflix Renewal Status and Expectations
Emily in Paris is a story of a 29-year-old girl who has shifted from Chicago to Paris for a job...
Kate Winslet’s Net Worth in 2026: Assets, Salary, and Relationships
With a huge net worth, Kate Winslet has been enjoying a fantastic career that has seen her successfully combine blockbusters...
NIL (Name, Image, and Likeness): Top 20 Highest-Paid College Athletes
The NCAA (National Collegiate Athletic Association) is a US-based government body that regulates the rules of sports in colleges and...
Porsche Recalls More than 173,500 Vehicles for Rear-Camera Malfunction
By Rob Sabo Porsche Cars North America, Inc. has issued a recall of 173,538 vehicles manufactured during the past six...
Chief Justice Roberts Says Americans Continue to Admire the Constitution
By Matthew Vadum Chief Justice John Roberts said on Dec. 31 that as the United States prepares to celebrate its...
US Rings in New Year as the World Welcomes 2026
By Troy Myers and Joseph Lord The East Coast rang in 2026 as the clock struck midnight on New Year’s...